Free Trial
OTCMKTS:NMRD

Nemaura Medical Q3 2024 Earnings Results & Report

Nemaura Medical logo
$0.0001 0.00 (0.00%)
As of 11/9/2026 02:59 PM Eastern

Nemaura Medical reported Q3 2024 earnings on February 12, 2024. The company reported EPS of -$0.12.

Earnings Announcement Details

Quarter
Q3 2024

Nemaura Medical EPS Results

Actual EPS
-$0.12
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Nemaura Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Nemaura Medical's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Nemaura Medical Q3 2024 Earnings FAQ

Nemaura Medical (OTCMKTS:NMRD) reported earnings of -$0.12 per share for Q3 2024. The report was announced on Monday, February 12, 2024.

Nemaura Medical's next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nemaura Medical on the company's earnings history page.

Nemaura Medical Earnings Headlines

NMRD Nemaura Medical Inc.
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
Nemaura Medical Inc (NMRD)
NXNN Nexeon Medsystems Inc
See More Nemaura Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nemaura Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nemaura Medical and other key companies, straight to your email.

About Nemaura Medical

Nemaura Medical (OTCMKTS:NMRD), Inc. is a medical technology company focused on developing wearable solutions for diabetes and metabolic health monitoring. Its principal product is SugarBEAT, a non-invasive glucose monitoring system designed to provide continuous or periodic glucose readings without the need for traditional finger-stick testing.

SugarBEAT is designed to use a disposable skin patch, a reusable sensor transmitter and a software application to collect and display glucose information. The company has also described applications for the technology in diabetes management, prediabetes monitoring and broader wellness programs.

Nemaura Medical has pursued regulatory clearances and commercial opportunities in international markets, including the United Kingdom and Europe. The company is headquartered in Fremont, California. Public information about its current commercial operations, product availability and leadership may be limited, and the regulatory status of its products can vary by geography.

View Nemaura Medical Profile